Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 19/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 19/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 19/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | PDXK | O00764 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313429 | 0.91 | NR4A3 (0.56) | NR4A3FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL6312659 | 0.88 | FGFR1 (0.52) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL6313878 | 0.81 | NR4A3 (0.57) | NR4A3FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL6312652 | 0.79 | FGFR1 (0.45) | NR4A3FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL6314248 | 0.79 | NR4A3 (0.59) | NR4A3 | |
| SCHEMBL4454445 | 0.77 | SLC9A1 (0.44) | FGFR1FGFR2FGFR3FGFR4KDR | |
| Hydrochloric Acid SCHEMBL6320007 | 0.76 | SLC9A1 (0.43) | FGFR1FGFR2FGFR3FGFR4KDR | |
| SCHEMBL6313370 | 0.76 | NR4A3 (0.61) | NR4A3FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL6313865 | 0.76 | NR4A3 (0.57) | NR4A3FGFR1FGFR2FGFR3FGFR4 | |
| SCHEMBL4454442 | 0.75 | FGFR1 (0.42) | FGFR1FGFR2FGFR3FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | NR4A3 2011/4885FGFR1 2482/4885FGFR2 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.